Facebook Instagram Linkedin Twitter Youtube
  • Home
  • Equities By Sectors
    • Basic Materials
    • Communication Services
    • Consumer Cyclical
    • Consumer Defensive
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Utilities
  • Thematics
  • Interviews
  • About Avise Equities
    • Career
  • Equity Research
  • Contact us
Search

LogoAvise AnalyticsWe value your company

  • About Avise
  • Meet Us
  • Events
  • Login / Subscribe
  • Home
  • Equities
  • Thematics
  • Interviews

  • About Avise Equities
  • Equity Research
  • Contact us

EQUITIES

EQUITIES BY SECTOR

Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities

THEMATICS

LATEST

Content coming soon.

INTERVIEWS

LATEST

Videos
08 . 13 . 2019
The Future of Hepatitis-B Treatment [ MUST WATCH ]
Videos
08 . 13 . 2019
A Future without Chronic Pain [MUST WATCH]
Videos
08 . 13 . 2019
Rising Problems & Innovations in the Treatment of Stroke – [Health Matters]

ABOUT AVISE EQUITIES

  • About Avise Equities
  • Career
“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Financial Director

LogoAvise AnalyticsWe value your company

Exclusive Content:

The Future of Hepatitis-B Treatment [ MUST WATCH ]

November 8, 2024 0

A Future without Chronic Pain [MUST WATCH]

August 13, 2019 0

Rising Problems & Innovations in the Treatment of Stroke – [Health Matters]

August 13, 2019 0

Biotechnology

Research in Biologics and Small Molecules aim to unravels the genetics...

Avise Analytics - June 3, 2019 0
Biotechnology

Can Cara Therapeutics buck the trend?

Avise Analytics - May 28, 2019 0
Biotechnology

Emerging Treatment Paradigms in Focal Segmental Glomerulosclerosis (FSGS)

Avise Analytics - May 24, 2019 0
Biotechnology

Research in Clonidine shows promise in the treatment of Sciatica

Avise Analytics - May 23, 2019 0
Biotechnology

G1 Therapeutics stock soars on news of NDA for Triaciclib

Avise Analytics - May 23, 2019 0
Biotechnology

Cortexyme: Addressing Unmet Needs in the Alzheimer’s Market

Avise Analytics - May 16, 2019 0
Biotechnology

LogicBio Therapeutics: Potential breakthrough in the Treatment of Methylmalonic Acidemia (MMA).

Avise Analytics - May 14, 2019 0
Biotechnology

Zolmitriptan Derivatives and Novel Drug Delivery Systems Aim to treat Acute...

Avise Analytics - May 8, 2019 0
Cannabis

Curaleaf Holding: Forging the largest acquisition in U.S cannabis landscape

Avise Analytics - May 6, 2019 0
Biotechnology

Recent Advances in Gene Therapy and Small Molecule Inhibitors show promise...

Avise Analytics - May 4, 2019 0
1234...8Page 3 of 8

Recent Comments

  • Marina Torres on 5 Promising Stocks In The Stroke Management Industry
  • Finlay Cedar on New Age Therapeutics Offer Hope to Patients of Multiple Sclerosis
  • Tshepo Prence on New therapeutics promise respite to patients suffering from COPD
  • Finlay Cedar on Is a cure for Alopecia Areata on the horizon? New research shows promise
  • Anton on THE FUTURE OF HEPATITIS-B TREATMENT [ MUST WATCH ]

EDITOR PICKS

Parcel Pal Technologies – On the Quick Road to Success

June 26, 2019

Gene Therapy offers Cure for Bubble Boy Syndrome

June 20, 2019

Curaleaf Holding: Forging the largest acquisition in U.S cannabis landscape

May 6, 2019

POPULAR POSTS

New therapeutics promise respite to patients suffering from COPD

February 27, 2019

New Age Therapeutics Offer Hope to Patients of Multiple Sclerosis

February 13, 2019

Is a cure for Alopecia Areata on the horizon? New research...

March 22, 2019

POPULAR CATEGORY

  • Biotechnology61
  • Clinical Trials59
  • FDA58
  • Trending57
  • IND52
  • Results48
  • Industry44
  • NDA37
  • Menu Client20
ABOUT US
Founded in 2012, Avise Analytics is the fastest growing equity research firm that authors institutional quality equity research reports, with special focus on Nano-Cap and Micro-Cap companies that are undervalued and lack adequate coverage. Avise is an approved research contributor on premier investor platforms such as Thomson Reuters, Factset and CaptialIQ.
Contact us: info@aviseanalytics.com
FOLLOW US
Facebook Instagram Linkedin Twitter Youtube
  • Disclaimer
  • Privacy
  • Contact Us
© Copyright 2019 aviseanalytics.com | All Rights Reserved.

REQUEST FREE COVERAGE

We also publish independent equity research reports, articles and interview videos on micro cap and small cap companies based on our initial research and investors interest.

We encourage OTC or NASDAQ based PUBCOS to reach out for a free coverage report.

EMAIL US

GET ON THE LIST

Join our mailing list for latest coverage reports and articles, and our special coverage videos of daily market analysis on small cap companies - "Lastday Movers"

    WORK WITH US

    We are looking for talented interns to learn and help investors find valuable companies.

    APPLY